Clinical Trial Update: Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3 [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating dolutegravir/lamivudine for ART-naïve HIV-1 infected patients with CD4 counts ≤200 cells/mm³ has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Dovato (dolutegravir/lamivudine)

Snippet

Sponsor: Fundación Huésped | Conditions: HIV-1-infection | Phase 4 | Status: COMPLETED | Results posted: 2025-07-30